Do analysts rate PFSA or VBIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Valion Bio, Inc. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, PFSA or VBIO?

Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa N/A N/A -$35.82M -$4.24 thousand N/A Valion Bio, Inc. Common Stock N/A N/A -$8.88M -$6.68 N/A

Is PFSA or VBIO more profitable?

Profusa's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Valion Bio, Inc. Common Stock N/A -138.10% -63.67%

Does the media favor PFSA or VBIO?

In the previous week, Profusa and Profusa both had 1 articles in the media. Profusa's average media sentiment score of 0.00 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profusa 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Valion Bio, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BJDX or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, BJDX or PFSA?

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bluejay Diagnostics N/A N/A -$6.85M -$11.63 N/A Profusa N/A N/A -$35.82M -$4.24 thousand N/A

Is BJDX or PFSA more profitable?

Profusa's return on equity of 0.00% beat Bluejay Diagnostics' return on equity. Company Net Margins Return on Equity Return on Assets Bluejay Diagnostics N/A -144.27% -115.00% Profusa N/A N/A -1,348.07%

Does the media refer more to BJDX or PFSA?

In the previous week, Bluejay Diagnostics had 4 more articles in the media than Profusa. MarketBeat recorded 5 mentions for Bluejay Diagnostics and 1 mentions for Profusa. Bluejay Diagnostics' average media sentiment score of 0.84 beat Profusa's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profusa 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer PFSA or RBOT?

Vicarious Surgical has a consensus target price of $7.00, indicating a potential upside of 3,437.14%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Vicarious Surgical 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable valuation & earnings, PFSA or RBOT?

Vicarious Surgical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa N/A N/A -$35.82M -$4.24 thousand N/A Vicarious Surgical N/A N/A -$63.22M -$6.69 N/A

Is PFSA or RBOT more profitable?

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Vicarious Surgical N/A -184.13% -112.50%

Does the media favor PFSA or RBOT?

In the previous week, Vicarious Surgical had 1 more articles in the media than Profusa. MarketBeat recorded 2 mentions for Vicarious Surgical and 1 mentions for Profusa. Profusa's average media sentiment score of 0.00 beat Vicarious Surgical's score of -0.14 indicating that Profusa is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Profusa 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vicarious Surgical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend LYRA or PFSA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is LYRA or PFSA more profitable?

Profusa has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Profusa's return on equity of 0.00% beat Lyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lyra Therapeutics -5,491.17% -1,010.91% -58.92% Profusa N/A N/A -1,348.07%

Do analysts prefer PFSA or DYNT?

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Profusa. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Profusa 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dynatronics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, PFSA or DYNT?

Dynatronics has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Profusa N/A N/A -$35.82M -$4.24 thousand N/A Dynatronics $33.60M 0.00 -$2.70M -$1.35 N/A

Is PFSA or DYNT more profitable?

Profusa has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Profusa's return on equity of 0.00% beat Dynatronics' return on equity. Company Net Margins Return on Equity Return on Assets Profusa N/A N/A -1,348.07% Dynatronics -8.35% -41.81% -9.56%

Profusa (PFSA) Competitors

$1.73 -0.13 (-6.99%)

Closing price 07/17/2026 04:00 PM Eastern

Extended Trading

$1.81 +0.08 (+4.57%)

As of 07/17/2026 07:55 PM Eastern

Compare

PFSA vs. VBIO, BJDX, RBOT, LYRA, and DYNT

Should you buy Profusa stock or one of its competitors? MarketBeat compares Profusa with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Profusa include Valion Bio, Inc. Common Stock (VBIO), Bluejay Diagnostics (BJDX), Vicarious Surgical (RBOT), Lyra Therapeutics (LYRA), and Dynatronics (DYNT). These companies are all part of the "medical equipment" industry.

How does Profusa compare to Valion Bio, Inc. Common Stock?

Profusa (NASDAQ:PFSA) and Valion Bio, Inc. Common Stock (NASDAQ:VBIO) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Profusa and Profusa both had 1 articles in the media. Profusa's average media sentiment score of 0.00 equaled Valion Bio, Inc. Common Stock'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Valion Bio, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.8% of Profusa shares are owned by institutional investors. Comparatively, 4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 0.8% of Profusa shares are owned by insiders. Comparatively, 2.2% of Valion Bio, Inc. Common Stock shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profusa has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market. Comparatively, Valion Bio, Inc. Common Stock has a beta of 1.82, meaning that its share price is 82% more volatile than the broader market.

Valion Bio, Inc. Common Stock is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A
Valion Bio, Inc. Common Stock	N/A	N/A	-$8.88M	-$6.68	N/A

Profusa's return on equity of 0.00% beat Valion Bio, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Valion Bio, Inc. Common Stock	N/A	-138.10%	-63.67%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Valion Bio, Inc. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Valion Bio, Inc. Common Stock beats Profusa on 5 of the 8 factors compared between the two stocks.

How does Profusa compare to Bluejay Diagnostics?

Bluejay Diagnostics (NASDAQ:BJDX) and Profusa (NASDAQ:PFSA) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Bluejay Diagnostics has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Profusa has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market.

Profusa's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bluejay Diagnostics	N/A	-144.27%	-115.00%
Profusa	N/A	N/A	-1,348.07%

In the previous week, Bluejay Diagnostics had 4 more articles in the media than Profusa. MarketBeat recorded 5 mentions for Bluejay Diagnostics and 1 mentions for Profusa. Bluejay Diagnostics' average media sentiment score of 0.84 beat Profusa's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bluejay Diagnostics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 6.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 0.8% of Profusa shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bluejay Diagnostics	N/A	N/A	-$6.85M	-$11.63	N/A
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bluejay Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bluejay Diagnostics beats Profusa on 8 of the 10 factors compared between the two stocks.

How does Profusa compare to Vicarious Surgical?

Profusa (NASDAQ:PFSA) and Vicarious Surgical (NYSE:RBOT) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Profusa's return on equity of 0.00% beat Vicarious Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Vicarious Surgical	N/A	-184.13%	-112.50%

9.8% of Profusa shares are held by institutional investors. Comparatively, 47.3% of Vicarious Surgical shares are held by institutional investors. 0.8% of Profusa shares are held by company insiders. Comparatively, 11.1% of Vicarious Surgical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Vicarious Surgical had 1 more articles in the media than Profusa. MarketBeat recorded 2 mentions for Vicarious Surgical and 1 mentions for Profusa. Profusa's average media sentiment score of 0.00 beat Vicarious Surgical's score of -0.14 indicating that Profusa is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Profusa	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vicarious Surgical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vicarious Surgical has a consensus target price of $7.00, indicating a potential upside of 3,437.14%. Given Vicarious Surgical's stronger consensus rating and higher possible upside, analysts clearly believe Vicarious Surgical is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Vicarious Surgical	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Vicarious Surgical is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A
Vicarious Surgical	N/A	N/A	-$63.22M	-$6.69	N/A

Profusa has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Vicarious Surgical has a beta of 1.88, meaning that its stock price is 88% more volatile than the broader market.

Summary

Vicarious Surgical beats Profusa on 8 of the 12 factors compared between the two stocks.

How does Profusa compare to Lyra Therapeutics?

Lyra Therapeutics (NASDAQ:LYRA) and Profusa (NASDAQ:PFSA) are both small-cap medical equipment companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

95.6% of Lyra Therapeutics shares are owned by institutional investors. Comparatively, 9.8% of Profusa shares are owned by institutional investors. 3.3% of Lyra Therapeutics shares are owned by insiders. Comparatively, 0.8% of Profusa shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lyra Therapeutics has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Profusa has a beta of 0.46, meaning that its share price is 54% less volatile than the broader market.

Profusa has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -5,491.17%. Profusa's return on equity of 0.00% beat Lyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-5,491.17%	-1,010.91%	-58.92%
Profusa	N/A	N/A	-1,348.07%

In the previous week, Profusa had 1 more articles in the media than Lyra Therapeutics. MarketBeat recorded 1 mentions for Profusa and 0 mentions for Lyra Therapeutics. Lyra Therapeutics' average media sentiment score of 0.00 equaled Profusa'saverage media sentiment score.

Company	Overall Sentiment
Lyra Therapeutics	Neutral
Profusa	Neutral

Profusa has lower revenue, but higher earnings than Lyra Therapeutics. Lyra Therapeutics is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$600K	1.54	-$93.43M	-$19.15	N/A
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A

Summary

Lyra Therapeutics beats Profusa on 7 of the 12 factors compared between the two stocks.

How does Profusa compare to Dynatronics?

Profusa (NASDAQ:PFSA) and Dynatronics (NASDAQ:DYNT) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

Given Dynatronics' higher probable upside, analysts plainly believe Dynatronics is more favorable than Profusa.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Profusa	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dynatronics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Dynatronics has higher revenue and earnings than Profusa. Profusa is trading at a lower price-to-earnings ratio than Dynatronics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Profusa	N/A	N/A	-$35.82M	-$4.24 thousand	N/A
Dynatronics	$33.60M	0.00	-$2.70M	-$1.35	N/A

Profusa has a beta of 0.46, suggesting that its share price is 54% less volatile than the broader market. Comparatively, Dynatronics has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

9.8% of Profusa shares are held by institutional investors. Comparatively, 4.2% of Dynatronics shares are held by institutional investors. 0.8% of Profusa shares are held by company insiders. Comparatively, 2.9% of Dynatronics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profusa has a net margin of 0.00% compared to Dynatronics' net margin of -8.35%. Profusa's return on equity of 0.00% beat Dynatronics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Profusa	N/A	N/A	-1,348.07%
Dynatronics	-8.35%	-41.81%	-9.56%

In the previous week, Profusa had 1 more articles in the media than Dynatronics. MarketBeat recorded 1 mentions for Profusa and 0 mentions for Dynatronics. Profusa's average media sentiment score of 0.00 equaled Dynatronics'average media sentiment score.

Company	Overall Sentiment
Profusa	Neutral
Dynatronics	Neutral

Summary

Profusa beats Dynatronics on 7 of the 13 factors compared between the two stocks.

Get Profusa News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PFSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PFSA vs. The Competition

Export

Metric	Profusa	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$322K	$3.19B	$4.40B	$12.28B
Dividend Yield	N/A	N/A	37.90%	9.34%
P/E Ratio	0.00	21.97	23.70	23.92
Price / Sales	N/A	20.43	92.98	89.30
Price / Cash	N/A	9.02	164.16	60.41
Price / Book	0.00	5.84	12.18	6.18
Net Income	-$35.82M	$23.43M	$121.47M	$332.29M
7 Day Performance	-18.40%	-5.43%	-1.12%	-2.05%
1 Month Performance	-61.56%	-7.50%	-2.65%	-2.18%
1 Year Performance	N/A	3.17%	9.79%	17.67%

Profusa Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PFSA Profusa	0.0502 of 5 stars	$1.73 -7.0%	N/A	N/A	$322K	N/A	N/A	2	Short Interest Increase Gap Down
VBIO Valion Bio, Inc. Common Stock	0.6002 of 5 stars	$0.45 -3.9%	N/A	-87.5%	$1.50M	$780K	N/A	10	Short Interest Decrease Gap Up
BJDX Bluejay Diagnostics	1.0926 of 5 stars	$1.35 +8.0%	N/A	-76.9%	$1.29M	N/A	N/A	9	News Coverage Analyst Upgrade Short Interest Increase
RBOT Vicarious Surgical	1.6398 of 5 stars	$0.18 +6.1%	$7.00 +3,900.0%	-98.1%	$1.18M	N/A	N/A	210	News Coverage Gap Down
LYRA Lyra Therapeutics	N/A	$0.50 +33.6%	N/A	-93.4%	$888K	$600K	N/A	50	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PFSA) was last updated on 7/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Profusa (PFSA) Competitors

PFSA vs. VBIO, BJDX, RBOT, LYRA, and DYNT

How does Profusa compare to Valion Bio, Inc. Common Stock?

Summary

How does Profusa compare to Bluejay Diagnostics?

Summary

How does Profusa compare to Vicarious Surgical?

Summary

How does Profusa compare to Lyra Therapeutics?

Summary

How does Profusa compare to Dynatronics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Profusa (PFSA) Competitors

PFSA vs. VBIO, BJDX, RBOT, LYRA, and DYNT

How does Profusa compare to Valion Bio, Inc. Common Stock?

Does the media favor PFSA or VBIO?

Do insiders & institutionals have more ownership in PFSA or VBIO?

Which has more risk & volatility, PFSA or VBIO?

Which has preferable earnings and valuation, PFSA or VBIO?

Is PFSA or VBIO more profitable?

Do analysts rate PFSA or VBIO?

Summary

How does Profusa compare to Bluejay Diagnostics?

Which has more volatility and risk, BJDX or PFSA?

Is BJDX or PFSA more profitable?

Does the media refer more to BJDX or PFSA?

Do institutionals and insiders have more ownership in BJDX or PFSA?

Which has better earnings and valuation, BJDX or PFSA?

Do analysts prefer BJDX or PFSA?

Summary

How does Profusa compare to Vicarious Surgical?

Is PFSA or RBOT more profitable?

Do insiders and institutionals believe in PFSA or RBOT?

Does the media favor PFSA or RBOT?

Do analysts prefer PFSA or RBOT?

Which has preferable valuation & earnings, PFSA or RBOT?

Which has more volatility and risk, PFSA or RBOT?

Summary

How does Profusa compare to Lyra Therapeutics?

Do analysts recommend LYRA or PFSA?

Do insiders & institutionals have more ownership in LYRA or PFSA?

Which has more risk & volatility, LYRA or PFSA?

Is LYRA or PFSA more profitable?

Does the media refer more to LYRA or PFSA?

Which has preferable valuation & earnings, LYRA or PFSA?

Summary

How does Profusa compare to Dynatronics?

Do analysts prefer PFSA or DYNT?

Which has higher earnings and valuation, PFSA or DYNT?

Which has more risk & volatility, PFSA or DYNT?

Do institutionals & insiders have more ownership in PFSA or DYNT?

Is PFSA or DYNT more profitable?

Does the media prefer PFSA or DYNT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PFSA vs. The Competition

Profusa Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools